Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure

Thrombosis Research

Volumn 121, Issue 5, 2008, Pages 611-615

  Vila, Virtudes ^a   Sales, Vicenta Martínez ^a   Almenar, Luis ^a   Lázaro, Ignacio Sánchez ^a   Villa, Piedad ^a   Reganon, Edelmiro ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Endothelial dysfunction; Heart failure; Oral anticoagulation therapy; Thrombospondin 1; von Willebrand factor

Indexed keywords

ANTICOAGULANT AGENT; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; INTERLEUKIN 6; PROTHROMBIN; THROMBOPLASTIN; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART FAILURE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR;

EID: 39749128509     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.06.011     Document Type: Article

References (27)

1. Anker S.D., and Von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
2. Vasan R.S., Sullivan L.M., Roubenoff R., Dinarello C.A., Harris T., Benjamin E.J., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
3. Chong A.Y., Blann A.D., and Lip G.Y. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 96 (2003) 253-267
4. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., and Lip G.Y. Endothelial dysfunction and damage in chronic heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110 (2004) 1794-1798
5. Lip G.Y., and Blann A.D. Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'. Ann Med 36 (2004) 119-125
6. Gabay C., and Kusner I. Acute-phase proteins and another systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
7. Ernst E., and Resch K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118 (1993) 956-963
8. Sadler J.E. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67 (1998) 395-424
9. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 72 (1996) 341-348
10. Xie L., Chesterman C.N., and Hogg P.J. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 193 (2001) 1341-1349
11. Pimanda J.E., Annis D.S., Raftery M., Mosher D.F., Chesterman C.N., and Hogg P.J. The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood 100 (2002) 2832-2838
12. Pimanda J.E., Ganderton T., Maekawa A., Yap C.L., Lawler J., Kershaw G., et al. Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 279 (2004) 21439-21448
13. Davis C.J., Gurbel P.A., Gattis W.A., Fuzaylov S.Y., Nair G.V., O'Connor C.M., et al. Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. Int J Cardiol 75 (2000) 15-21
14. De Lorenzo F., Saba N., and Kakkar V.V. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. Drugs 63 (2003) 565-576
15. Reganon E., Vila V., and Aznar J. Gelification of fibrinogen in plasma. A kinetic study by turbidity measurement. Haemostasis 14 (1984) 170-178
16. Cugno M., Mari D., Meroni P.L., Gronda E., Vicari F., Frigerio M., et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol 126 (2004) 85-92
17. Reganon E., Vila V., Ferrando F., Martinez-Sales V., Fayos L., Ruano M., et al. Elevated high molecular weight fibrinogen in plasma is predictive of coronary ischemic events after acute myocardial infarction. Thromb Haemost 82 (1999) 1403-1405
18. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1799-1809
19. Bruhn H.D., Liebsch J., and Wagner C. Documentation of hypocoagulability by measurement of prothrombin fragment F1 + 2 when introducing oral anticoagulant therapy. Thromb Res 68 (1992) 317-319
20. Vischer U.M. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 4 (2006) 1186-1193
21. Gibbs C.R., Blann A.D., Watson R.D., and Lip G.Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 103 (2001) 1746-1751
22. Lip G.Y., and Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 34 (1997) 255-265
23. Whincup P.H., Danesh J., Walker M., Lennon L., Thomson A., Appleby P., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23 (2002) 1764-1770
24. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 1102-1108
25. Chong A.Y., Freestone B., Patel J., Lim H.S., Hughes E., Blann A.D., et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97 (2006) 671-675
26. Kopp H.G., Hooper AT., Broekman M.J., Avecilla S.T., Petit I., Luo M., et al. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J Clin Invest 116 (2006) 3277-3291
27. Furlan M., Robles R., and Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 (1996) 4223-4234